<DOC>
	<DOCNO>NCT02371590</DOCNO>
	<brief_summary>This phase 1/2 study patient CLL ( SLL ) previously treat . This study evaluate whether obinutuzumab lenalidomide safe tolerable set induce complete clinical response .</brief_summary>
	<brief_title>Lenalidomide Obinutuzumab Previously Untreated CLL</brief_title>
	<detailed_description>This phase 1/2 study patient CLL ( SLL ) previously treat . The primary endpoint determine safety tolerability regimen determine complete response ( CR ) therapy . The secondary endpoint assess impact treatment progression free overall survival Eligible patient receive obinutuzumab 6 x 28 day cycle . Patients also receive lenalidomide orally daily day 8-28 28 day cycle . The start dose patient 5 mg PO daily . At start cycle , intra-patient dose-escalation maximum 25mg daily , tolerate .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<criteria>Main 1 . Clinical phenotypic verification B cell CLL SLL measurable disease . 2 . Prior therapy : prior CLL therapy . 3 . Patients must progressive disease base 2008 iwCLL definition one following : Symptomatic progressive splenomegaly Symptomatic lymph node , nodal cluster , progressive lymphadenopathy Progressive anemia ( hemoglobin ≤ 11 g/dL ) Progressive thrombocytopenia ( platelet ≤ 100 x 109/L ) Weight loss &gt; 10 % body weight precede 6 month period Fatigue attributable CLL Fever night sweat &gt; 2 week without evidence infection Progressive lymphocytosis increase &gt; 50 % 2month period anticipate doubling time le 6 month . Able take aspirin ( 81mg 325mg ) daily , warfarin , low molecular weight heparin , equivalent anticoagulation prophylactic medication . All study participant must register mandatory Revlimid REMS program , willing able comply requirement REMS . Females childbearing potential ( FCBP ) must negative serum urine pregnancy test sensitivity least 50 mIU/mL within 10 14 day prior within 24 hour prior start Revlimid must either commit continue abstinence heterosexual intercourse begin TWO acceptable method birth control . Females reproductive potential must adhere scheduled pregnancy test require Revlimid REMS program . ECOG performance status 02 . Adequate hematologic function Adequate renal function Adequate hepatic function Pregnant breastfeed woman enter study due risk fetal teratogenic adverse event see animal/human study . Women childbearing age must obtain pregnancy test pregnant breast feeding female exclude . Known hypersensitivity thalidomide lenalidomide ( applicable ) , include development erythema nodosum desquamate rash take thalidomide similar drug . Deep vein thrombosis superficial thrombophlebitis cause current anticoagulation therapy time screen . Patients currently receive another investigational agent exclude . Current infection require parenteral antibiotic . Known seropositive active viral infection human immunodeficiency virus ( HIV ) ; know active infection hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) base detectable viral load . Patients seropositive hepatitis B virus vaccine passive immunization intravenous immunoglobulin ( IVIG ) eligible . Active malignancy within previous 2 year ( completely resect nonmelanoma skin cancer carcinoma situ ) . Known central nervous system ( CNS ) involvement malignancy . Untreated autoimmunity autoimmune hemolytic anemia , immune thrombocytopenia . Insufficient recovery surgicalrelated trauma wound healing . Impaired cardiac function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>cancer</keyword>
	<keyword>lenalidomide</keyword>
	<keyword>obinutuzumab</keyword>
	<keyword>CLL</keyword>
</DOC>